healthcare VC @canaanpartners
Westport, CT
Joined March 2014
- Tweets246
- Following146
- Followers675
- Likes526
Colleen Cuffaro retweeted
Bonkers with excitement as we launch ticket sales for the 10th Annual NEVY Awards, welcoming you to celebrate 10 Mad Years with us!
Buy your ticket for NEVYs in Wonderland on 12/8 – inventory is limited: thenevys.com
#NEVYs22 #NEVYsInWonderland
Colleen Cuffaro retweeted
Cancer mutates a lot, Tyra Biosciences CEO Todd Harris said. And sometimes, that causes targeted therapies to stop working. On Wednesday, he unveiled a $106 million Series B round to address acquired resistance.
endpts.com/why-do-some-targe…
Colleen Cuffaro retweeted
Day One’s mission is centered around improving the landscape for pediatric cancers, an area that the company says pharma has left behind over the last several years.
endpts.com/with-rapid-progre…
THIS is why we do what we do.
Just announced: Promising results from @DayOneBio's Phase 1 study, and the stakes couldn't be higher. "Children with cancer and their families are waiting for more options," says CEO Jeremy Bender. Learn more: dayonebio.com/news/day-one-a…
Colleen Cuffaro retweeted
Announcing our $800M Fund XII - very grateful to my colleagues, our investors and all the incredible entrepreneurs we serve who helped make this new fund possible.
Colleen Cuffaro retweeted
We couldn’t be happier to have Jeremy formally back in the @canaanpartners family - friend, colleague and cancer-warrior! Childhood cancer-focused Day One snags Gilead alum Bender for CEO | FierceBiotech fiercebiotech.com/biotech/ch…
Colleen Cuffaro retweeted
Jackie Grant, an exceptional black woman PhD investor @Abingworthbio, discusses causes of the lack of racial diversity in #venturecapital and offers advice about how to make change. She nails the economic incentives, social pacts, and biases. @IAmBiotech #blm /n
Investing in racial diversity: a call to action to the venture capital community go.nature.com/39kyxm7
ALT The disparity in under-represented racial minorities on the investment teams in life science VC
Congrats to the Tizona team and @nkjellson!
Gilead wants access to the biotech’s other main asset, TTX-080. For this, it has penned a $300 million pact to acquire a 49.9% equity interest in Tizona, with an option to buy out the biotech in full for a further $1.25 billion fiercebiotech.com/biotech/pa…
Colleen Cuffaro retweeted
The FDA has approved 200 products for adult cancers in the last 20 years, but fewer than 10 new drugs specifically for children with cancer. Enter @DayOneBio, led by @JuliePapanek & @drsa, on a mission to change cancer care. Read on via @FierceBiotech fiercebiotech.com/biotech/da…
I remember the day @JuliePapanek first shared her idea for a pediatric oncology company with me. Amazing to witness her relentless pursuit of this noble cause. Congrats to Julie and the whole DayOne team! bit.ly/2zUNwFx
I don't tweet often, but this is hard not to tweet about
Arrakis Therapeutics Enters Strategic Collaboration and License Agreement with Roche for Multi-Target Program Utilizing RNA-Targeted Small Molecule Drug Discovery Platform arrakistx.com/news/press-rel…
Colleen Cuffaro retweeted
The NEVCA is proud to bring to you a compilation of all the latest resources related to Covid-19. From webinars to articles, this is the most up-to-date information for founders and investors from our community. Check it out here: bit.ly/NEVCAresourceguide
👏 welcome, Jacques! Looking forward to drugging some RNA with you.
Arrakis Therapeutics Appoints Jacques Dumas, Ph.D., as Senior Vice President, Drug Discovery arrakistx.com/news/press-rel…
A proud moment as a @NewEnglandVC board member - today marks the day that women make up 50% of this board. Check out the @BostonGlobe's article on how we are championing diversity in this industry. bit.ly/NEVCA-Board-Announcem…
congrats to my superstar colleagues @bdickins and @JuliePapanek on their promotions to GP!
Successful generational transition is a superpower of enduring VC firms. We’re thrilled to announce that @bdickins & @JuliePapanek have been promoted to General Partner. These 2 are thesis-driven investors that exemplify our high performance, low ego ethos canaan.com/latest/growth-fro…
The Arrakis team just keeps getting better!
Arrakis Therapeutics Appoints Katrine Bosley as Chairman of the Board of Directors arrakistx.com/news/press-rel…
Welcome, Nils!
From the start of his career through the development of a paradigm-shifting approach to cancer therapy, Nils Lonberg has brought together insights in drug development to address unmet clinical needs. We're thrilled he's joining Canaan as Exec in Residence. bit.ly/30O4DSz
Colleen Cuffaro retweeted
Our CEO @michael_gilman explores how Arrakis has
overcome the challenges of bringing RNA into play for
small-molecule drug discovery. Check out his blog post
on the Dark Matter blog.
arrakistx.com/darkmatter/